Recently, poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) have been approved by the US Food and Drug Administration for homologous recombination (HR)-deficient breast cancer induced by BRCA1/2 mutations5,6. This evidence concerns the gene BRCA1 and breast carcinoma.